A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart

Clinical Science

Volumn 112, Issue 11-12, 2007, Pages 607-616

  Nakamura, Kazuto ^a,b   Sata, Masataka ^a   Iwata, Hiroshi ^a   Sakai, Yoshiki ^c   Hirata, Yasunobu ^a   Kugiyama, Kiyotaka ^b   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Angiogenesis; Cardiovascular system; Hepatocyte growth factor (HGF); Ischaemia; Prostacyclin; Regenerative medicine; Vascular endothelial growth factor (VEGF)

Indexed keywords

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; BUCLADESINE; CYCLIC AMP; FORSKOLIN; GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIGATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; UMBILICAL VEIN; UPREGULATION;

ANIMALS; DILATATION, PATHOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPOPROSTENOL; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED STRAINS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; THROMBOXANE-A SYNTHASE; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34249829593     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20060301     Document Type: Article

References (47)

1. Freedman, S. and Isner, J. M. (2001) Therapeutic angiogenesis for ischemic cardiovascular disease. J. Mol. Cell. Cardiol. 33, 379-393
2. Losordo, D. W. and Dimmeler, S. (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease: part I: angiogenic cytokines. Circulation 109, 2487-2491
3. Khakoo, A. Y. and Finkel, T. (2005) Endothelial progenitor cells. Annu. Rev. Med. 56, 79-101
4. Ziegelhoeffer, T., Fernandez, B., Kostin, S. et al. (2004) Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ. Res. 94, 230-238
5. O'Neill, IV T. J., Wamhoff, B. R., Owens, G. K. and Skalak, T. C. (2005) Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. Circ. Res. 97, 1027-1035
6. Hughes, G. C., Biswas, S. S., Yin, B. et al. (2004) Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann. Thorac. Surg. 77, 812-818
7. Yamauchi, A., Ito, Y., Morikawa, M. et al. (2003) Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. J. Gene Med. 5, 994-1004
8. Matsumoto, K., Okazaki, H. and Nakamura, T. (1995) Novel function of prostaglandins as inducers of gene expression of HGF and putative mediators of tissue regeneration. J. Biochem. (Tokyo) 117, 458-464
9. Pai, R., Szabo, I. L., Soreghan, B. A., Atay, S., Kawanaka, H. and Tarnawski, A. S. (2001) PGE2 stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem. Biophys. Res. Commun. 286, 923-928
10. Mehrabi, M. R., Serbecic, N., Tamaddon, F. et al. (2002) Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc. Res. 56, 214-224
11. Makino, H., Aoki, M., Hashiya, N. et al. (2004) Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor. Hypertens. Res. 27, 85-91
12. Matsumoto, K., Morishita, R., Tomita, N. et al. (2002) Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue. J. Endocrinol. 175, 217-223
13. Coker, S. J., Parratt, J. R., Ledingham, I. M. and Zeitlin, I. J. (1981) Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291, 323-324
14. Johnson, III, G., Furlan, L. E., Aoki, N. and Lefer, A. M. (1990) Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. Circ. Res. 66, 1362-1370
15. de Deckere, E. A., Nugteren, D. H. and Ten Hoor, F. (1977) Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. Nature 268, 160-163
16. Pola, R., Gaetani, E., Flex, A. et al. (2004) Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. J. Mol. Cell. Cardiol. 36, 363-370
17. Hayashi, K., Nagamatsu, T., Oka, T. and Suzuki, Y. (1997) Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase. Jpn J. Pharmacol. 73, 73-82
18. Rudd, J. A., Qian, Y., Tsui, K. K. and Jones, R. L. (2000) Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon. Br. J. Pharmacol. 129, 782-790
19. Murakami, S., Nagaya, N., Itoh, T. et al. (2006) Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L59-L65
20. Imawaka, H. and Sugiyama, Y. (1998) Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. J. Pharmacol. Exp. Ther. 284, 949-957
21. Shiomi, T., Tsutsui, H., Hayashidani, S. et al. (2002) Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106, 3126-3132
22. Bishop, E. T., Bell, G. T., Bloor, S., Broom, I. J., Hendry, N. F. and Wheatley, D. N. (1999) An in vitro model of angiogenesis: basic features. Angiogenesis 3, 335-344
23. Cao, B., Su, Y., Oskarsson, M. et al. (2001) Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. U.S.A. 98, 7443-7448
24. Stiffey-Wilusz, J., Boice, J. A., Ronan, J., Fletcher, A. M. and Anderson, M. S. (2001) An ex vivo angiogenesis assay utilizing commercial porcine carotid artery: modification of the rat aortic ring assay. Angiogenesis 4, 3-9
25. Michael, L. H., Entman, M. L., Hartley, C. J. et al. (1995) Myocardial ischemia and reperfusion: a murine model. Am. J. Physiol. Heart Circ. Physiol. 269, H2147-H2154
26. Tanaka, K., Sata, M., Hirata, Y. and Nagai, R. (2003) Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ. Res. 93, 783-790
27. Youn, H. J., Rokosh, G., Lester, S. J., Simpson, P., Schiller, N. B. and Foster, E. (1999) Two-dimensional echocardiography with a 15-MHz transducer is a promising alternative for in vivo measurement of left ventricular mass in mice. J. Am. Soc. Echocardiogr. 12, 70-75
28. Sata, M., Nishimatsu, H., Suzuki, E. et al. (2001) Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J. 15, 2530-2532
29. Scherrer-Crosbie, M., Ullrich, R., Bloch, K. D. et al. (2001) Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 104, 1286-1291
30. Barandon, L., Couffinhal, T., Ezan, J. et al. (2003) Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation 108, 2282-2289
31. Shoji, M., Sata, M., Fukuda, D. et al. (2004) Temporal and spatial characterization of cellular constituents during neointimal hyperplasia after vascular injury: Potential contribution of bone-marrow-derived progenitors to arterial remodeling. Cardiovasc. Pathol. 13, 306-312
32. Nakano, N., Morishita, R., Moriguchi, A. et al. (1998) Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-β in blood vessels: potential role of HGF in cardiovascular disease. Hypertension 32, 444-451
33. Lee, R. J., Springer, M. L., Blanco-Bose, W. E., Shaw, R., Ursell, P. C. and Blau, H. M. (2000) VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102, 898-901
34. Carmeliet, P. (2000) VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat. Med. 6, 1102-1103
35. Thurston, G., Suri, C., Smith, K. et al. (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286, 2511-2514
36. Murohara, T., Ikeda, H., Duan, J. et al. (2000) Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest. 105, 1527-1536
37. Kalka, C., Masuda, H., Takahashi, T. T. et al. (2000) Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. U.S.A. 97, 3422-3427
38. Urbich, C. and Dimmeler, S. (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 95, 343-353
39. Tateno, K., Minamino, T., Toko, H. et al. (2006) Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ. Res. 98, 1194-1202
40. Morishita, R., Nakamura, S., Nakamura, Y. et al. (1997) Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 46, 138-142
41. Matsunaga, T., Gohda, E., Takebe, T. et al. (1994) Expression of hepatocyte growth factor is up-regulated through activation of a cAMP-mediated pathway. Exp. Cell Res. 210, 326-335
42. Van Belle, E., Witzenbichler, B., Chen, D. et al. (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97, 381-390
43. Xin, X., Yang, S., Ingle, G. et al. (2001) Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am. J. Pathol. 158, 1111-1120
44. Gille, J., Khalik, M., Konig, V. and Kaufmann, R. (1998) Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. J. Invest. Dermatol. 111, 1160-1165
45. Sakurai, S., Alam, S., Pagan-Mercado, G. et al. (2002) Retinal capillary pericyte proliferation and c-Fos mRNA induction by prostaglandin D2 through the cAMP response element. Invest. Ophthalmol. Vis. Sci. 43, 2774-2781
46. Skrinska, V. A., Lucas, F. V., Chisolm, G. M. and Hesse, B. L. (1986) Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. J. Lab. Clin. Med. 107, 187-193
47. Hayashi, S., Morishita, R., Nakamura, S. et al. (1999) Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 100, II301-II308